---
company: Jaguar Health, Inc.
ticker: JAGX
form: 8-K
filed: 2026-08-19
accession: 0001193125-26-356915
source: https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/
---

# Jaguar Health (JAGX) earnings release, August 19, 2026

Jaguar Health, Inc. (JAGX) · Form 8-K, Item 2.02 · Filed 2026-08-19 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/)

Jaguar Health Reports Second Quarter 2026 Financials

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027

REMINDER:

Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates (click here to register)

SAN FRANCISCO, CA / August 19, 2026

/

Jaguar Health, Inc.

(

NASDAQ: JAGX) (“Jaguar” or the “Company”) today reported its consolidated second-quarter 2026 financial results.

2026 SECOND QUARTER COMPANY FINANCIAL RESULTS:

Note Regarding Use of

Non-GAAP

Measures

The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP

EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

The Company defines non-GAAP

EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP

Recurring EBITDA as non-GAAP

EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP

EBITDA and non-GAAP

Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.

About Crofelemer

Crofelemer is the only oral

FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the

Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

About the Jaguar Health Family of Companies

Jaguar

Health, Inc. (“Jaguar”) develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and

Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo

Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal

Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Gelclair®

INDICATIONS

GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.

IMPORTANT SAFETY INFORMATION

You are encouraged to report negative side effects of prescription medical products to the FDA.

Visit www.fda.gov/safety/medwatch or call

1-855-273-0468.

Please see full Prescribing Information at: https://www.gelclairhcp.com/pdf/prescribing-information-instructions-for-use.pdf

Important Safety Information About Canalevia®

-CA1... (truncated)humans. Keep

Canalevia-CA1

(crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using

Canalevia-CA1, rule out infectious etiologies of diarrhea.

Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed.

It is a violation of Federal law to use this product other than as directed in the labeling.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number

141-552.

See full Prescribing Information at

Canalevia.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the clinical package for the NDA (New Drug Application) for crofelemer for MVID will be ready by end of 2026,

Jaguar’s expectation that submission of the NDA for crofelemer for MVID will take place in Q2 2027, Jaguar’s expectation that it will hold an investor webcast on August 19, 2026, and Jaguar’s expectation that its powder formulation of crofelemer utilized in the rare disease IF clinical trials will receive regulatory approval and may be approved for commercialization. In some cases, you can identify forward-looking statements by terms such as “may,”

“will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”

“believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions.

Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact: hello@jaguar.health

Jaguar-JAGX

## Financial statements

### Income Statement (Three Months Ending June 30, — 2026 SECOND QUARTER COMPANY FINANCIAL RESULTS: (in thousands))

| | Three Months Ending June 30, – 2026 | Three Months Ending June 30, – 2025 | $ change | % change |
|---|---:|---:|---:|---:|
| (in thousands, except per share amounts) | License and grant revenue, net | 43 | 43 | 0 | 0.0% |
| (in thousands, except per share amounts) | Product revenue, net | 1,182 | 2,936 | -1,754 | -60.0% |
| (in thousands, except per share amounts) | Total revenue, net | 1,225 | 2,979 | -1,754 | -59.0% |
| (in thousands, except per share amounts) | Loss from operations | -7,597 | -8,007 | 410 | -5.0% |
| (in thousands, except per share amounts) | Net loss attributable to common stockholders | -12,690 | -10,407 | -2,283 | 22.0% |
| (in thousands, except per share amounts) | Net loss per share, basic and diluted | -15.68 | -358.94 | 343 | -96.0% |
